H. Lundbeck Dividends and Buybacks
Dividend criteria checks 3/6
H. Lundbeck is a dividend paying company with a current yield of 2.7% that is well covered by earnings.
Key information
2.7%
Dividend yield
0.05%
Buyback Yield
| Total Shareholder Yield | 2.7% |
| Future Dividend Yield | 3.5% |
| Dividend Growth | 25.7% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 31% |
Recent dividend and buyback updates
Recent updates
Narrative Update • Jun 22
HLUN B: Neuroscience Pipeline Progress Will Support Future Upside Potential
Analysts have maintained their fair value estimate for H. Lundbeck at DKK 47.21.Analysis Article • Jun 18
H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data
H. Lundbeck (CPSE:HLUN B) stock is in focus after the company reported preliminary Phase II Part A data for asedebart in Cushing's disease, showing urinary free cortisol normalization in most evaluable patients. See our latest analysis for H. Lundbeck. The preliminary asedebart data arrives after a steady run in H. Lundbeck's stock, with the latest share price at DKK42.32, a 30 day share price return of 5.43% and a 90 day share price return of 13.95%, while the 1 year total shareholder return...
Narrative Update • Jun 06
HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple
Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.Analysis Article • May 24
H. Lundbeck's (CPH:HLUN B) Solid Earnings Have Been Accounted For Conservatively
H. Lundbeck A/S' ( CPH:HLUN B ) recent earnings report didn't offer any surprises, with the shares unchanged over the...Narrative Update • May 23
HLUN B: Neuroscience Pipeline Progress And Dividend Policy Will Support Future Upside
Analysts now estimate fair value for H. Lundbeck at about DKK47.21 per share, up from roughly DKK46.13.Analysis Article • May 15
Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
Narrative Update • May 05
HLUN B: Late-Stage Neurology Pipeline Will Support Future Margins
Analysts have nudged their fair value estimate for H. Lundbeck stock from DKK 61.99 to DKK 63.32, reflecting updated views on revenue growth, profit margins and future P/E assumptions.Narrative Update • Apr 20
HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook
Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.Narrative Update • Apr 05
HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins
Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.Narrative Update • Mar 22
HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion
Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.Narrative Update • Mar 08
HLUN B: Migraine Pipeline Progress Will Support Constructive Medium Term Upside Potential
Analysts have raised their H. Lundbeck price target from DKK 44.95 to DKK 46.13, citing updated assumptions around revenue growth, profit margins and future P/E as the main factors behind the change.Narrative Update • Feb 22
HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook
Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.Narrative Update • Feb 08
HLUN B: Weaker Long Term Revenue And Margin Outlook Will Pressure Shares
Analysts have reduced their price target on H. Lundbeck from €39.00 to €34.00, citing updated assumptions for revenue growth, profit margins, and a slightly higher discount rate, while keeping the forward P/E outlook broadly similar.Analysis Article • Feb 07
H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...Narrative Update • Jan 25
HLUN B: Pipeline And Guidance Updates Will Support Balanced Medium Term Outlook
Analysts have lifted their price target for H. Lundbeck from €45.55 to about €47.05, reflecting updated assumptions that include slightly lower revenue growth, a higher profit margin and a marginally adjusted forward P/E multiple.Analysis Article • Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Jan 11
HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook
Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.Narrative Update • Dec 27
HLUN B Will Benefit From Expanding Neurology Pipeline And Margin Improvements
Narrative Update on H. Lundbeck Analysts have modestly increased their price target on H.Narrative Update • Dec 13
HLUN B: Long Term Revenue Outlook Will Likely Weigh On Shares
Analysts have nudged their price target on H. Lundbeck up by approximately 1 currency unit to 39, citing a slightly higher projected profit margin and modestly richer future valuation multiples, even as they temper long term revenue growth expectations and apply a marginally higher discount rate.Analysis Article • Nov 22
The Strong Earnings Posted By H. Lundbeck (CPH:HLUN B) Are A Good Indication Of The Strength Of The Business
H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...Analysis Article • Nov 15
Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...Analysis Article • Oct 28
Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)
With a price-to-earnings (or "P/E") ratio of 13.2x H. Lundbeck A/S ( CPH:HLUN B ) may be sending bullish signals at the...Narrative Update • Sep 05
CNS Pipeline And Global Expansion Will Unlock Future Opportunities
With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.Analysis Article • Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...
New Narrative • Dec 04
Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth
Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, HLUN B has been paying a dividend for less than 10 years.
Growing Dividend: HLUN B's dividend payments have increased, but the company has only paid a dividend for 3 years.
Dividend Yield vs Market
| H. Lundbeck Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (HLUN B) | 2.7% |
| Market Bottom 25% (DK) | 1.5% |
| Market Top 25% (DK) | 4.1% |
| Industry Average (Pharmaceuticals) | 2.7% |
| Analyst forecast (HLUN B) (up to 3 years) | 3.5% |
Notable Dividend: HLUN B's dividend (2.7%) is higher than the bottom 25% of dividend payers in the Danish market (1.52%).
High Dividend: HLUN B's dividend (2.7%) is low compared to the top 25% of dividend payers in the Danish market (4.09%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (30.6%), HLUN B's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (23.6%), HLUN B's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/22 16:44 |
| End of Day Share Price | 2026/07/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
H. Lundbeck A/S is covered by 34 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rosie Turner | Barclays |
| Charles Pitman | Barclays |
| Emily Field | Barclays |